As median survival increases among patients with CF, clinicians must now be aware of previously uncommon comorbidities emerging as this patient population ages.Read More
Advancements in Interstitial Lung Disease (Podcast)
In a featured episode of Cleveland Clinic’s Respiratory Exchange podcast, Daniel Culver, DO, discusses the evolution in classification, diagnosis, treatment and management of interstitial lung disease.
Treprostinil: First Drug Approved for Patients with Pulmonary Hypertension and Interstitial Lung Disease
Compared with placebo, inhaled treprostinil was associated with lower risk of clinical worsening and fewer exacerbations of underlying lung disease during a 16-week treatment period.
Does Accurate Diagnosis Still Matter for Interstitial Lung Disease?
A multidisciplinary approach can uncover unsuspected diagnoses of interstitial lung disease. Many times this precision makes a difference in management strategy and patient outcomes.
A Paradigm Shift in the Treatment of Scleroderma-Associated Interstitial Lung Disease
Kristin Highland, MD, discusses new potential pathways to treat scleroderma-associated interstitial lung disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The Interstitial Lung Disease Clinic’s Patient-Focused Approach
An inside look into the ILD Clinic of a large, tertiary referral center.
How to Treat Idiopathic Pulmonary Fibrosis
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by offering an overview of available treatment modalities.
A Diagnostic Algorithm for Idiopathic Pulmonary Fibrosis
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by offering clues to diagnosing the disease.
Idiopathic Pulmonary Fibrosis: What PCPs Need To Know
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by reviewing the natural course of IPF.
Pulmonary Alveolar Proteinosis: A Rare Lung Disease
An expert in this rare lung disease offers an overview of pathophysiology and the clinical approach utilized in the Interstitial Lung Disease Program.
Cleveland Clinic Joins Pulmonary Fibrosis Foundation’s Care Center Network
Our multidisciplinary team treats local and national patients with this chronic and progressive lung disease.